Ambeed 大中华区 CN | ZH

中文 - ZH English - EN

Ambeed.cn

搜索

关键字搜索批量搜索

首页 收藏 购物车0
首页 /
抑制剂/激动剂
囊泡 肿瘤
/
干细胞
MAPK/ERK Pathway 帕金森与阿尔茨海默症 肿瘤生长增殖和凋亡 Notch
/ ERK / Tauroursodeoxycholate sodium

牛磺熊去氧胆酸钠 /Tauroursodeoxycholate sodium {[allProObj[0].p_purity_real_show]}

货号：A154752 同义名： 牛磺熊脱氧胆酸钠 / Tauroursodeoxycholic acid sodium;UR 906 sodium

Tauroursodeoxycholate sodium（Tauroursodeoxycholic acid；TUDCA）钠是一种内质网（ER）应激抑制剂，显著减少caspase-3和caspase-12等凋亡分子的表达，并抑制ERK。

Tauroursodeoxycholate sodium 化学结构 CAS号：35807-85-3
Tauroursodeoxycholate sodium 化学结构
CAS号：35807-85-3
Tauroursodeoxycholate sodium 3D分子结构
CAS号：35807-85-3
Tauroursodeoxycholate sodium 化学结构 CAS号：35807-85-3
Tauroursodeoxycholate sodium 3D分子结构 CAS号：35807-85-3
规格 价格 会员价 库存 数量
{[ item.pr_size ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]} 		{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_am, item.pr_size) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} 现货 咨询 - +
购物车0 收藏 询单

Tauroursodeoxycholate sodium 纯度/质量文件 产品仅供科研

货号：A154752 标准纯度： {[allProObj[0].p_purity_real_show]}
批次查询： 批次纯度:

全球学术期刊中引用的产品

• Cell Host Microbe, 2024. Ambeed. [ A163338 ]
• Cancer Res., 2024. Ambeed. [ A295334 ]
• J. Pharm. Investig., 2024. Ambeed. [ A221527 , A691302 , A272538 , A187261 ]
• J. Fungi, 2024, 10(11): 751. Ambeed. [ A796919 ]
• JBC, 2024, 107935. Ambeed. [ A194396 ]
更多 >
产品名称 ERK ↓ ERK1 ↓ ERK2 ↓ ERK5 ↓ 其他靶点 纯度
DEL-22379 +

ERK, IC50: 0.5 μM

 		+

ERK, IC50: 0.5 μM

 		98%
Pluripotin ++

ERK1, Kd: 98 nM

 		RasGAP 98+%
FR 180204 +

ERK1, Ki: 0.31 μM

 		++

ERK2, Ki: 0.14 μM

 		98%
Ravoxertinib +++

ERK1, IC50: 1.1 nM

 		++++

ERK2, IC50: 0.3 nM

 		99%+
SCH772984 +++

ERK1, IC50: 4 nM

 		++++

ERK2, IC50: 1 nM

 		99%+
Temuterkib +++

ERK1, IC50: 5 nM

 		+++

ERK2, IC50: 5 nM

 		99%+
VX-11e +++

ERK2, Ki: <2 nM

 		99%+
Ulixertinib ++++

ERK2, IC50: <0.3 nM

 		99%+
XMD17-109 ++

ERK5, IC50: 162 nM

 		99%+
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

Tauroursodeoxycholate sodium 生物活性

描述 Tauroursodeoxycholate Sodium is a water-soluble bile acid used in the treatment of gallstones and cirrhosis. Tauroursodeoxycholate (TUDC) is well known to protect against glycochenodeoxycholate (GCDC)-induced apoptosis in rat hepatocytes. While GCDC upregulated the expression of several pro-inflammatory genes, co-perfusion with TUDC increased the expression of pro-proliferative and anti-apoptotic p53 target genes[3]. After the induction of colitis for 24h, the mice were administrated orally with tauroursodeoxycholate (20, 40 and 60mg/kg) and sulfasalazine (500mg/kg) by gavage for 7 consecutive days. Treatment with different doses of tauroursodeoxycholate (20, 40 and 60mg/kg) significantly improved the body weight change, decreased the macroscopic and histopathological scores. Compared with the model group, the accumulation of MPO (myeloperoxidase) activity, the colonic tissue levels of IL-1β, IFN-γ and TNF-α were significantly reduced in the tauroursodeoxycholate treated groups. Moreover, tauroursodeoxycholate assuaged the symptoms of colitis[4]. Tauroursodeoxycholate (360 μ mol / kg, i.v.) significantly inhibited the decrease of bile flow and increased the activities of serum alkaline phosphatase, leucine aminopeptidase and alanine aminotransferase, as well as the concentrations of cholesterol, phospholipids and bile acids in rats with bile obstruction induced by phalloidin[5].

Tauroursodeoxycholate sodium 临床研究

NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT03127514 Amyotrophic Lateral Sclerosis ... 展开 >> Motor Neuron Disease Neuromuscular Diseases Neurodegenerative Diseases Spinal Cord Diseases TDP-43 Proteinopathies Nervous System Diseases Central Nervous System Diseases 收起 << Phase 2 Recruiting May 2019 -
NCT00771901 - Completed - -
NCT03533257 Alzheimer Disease Phase 2 Recruiting September 1, 2020 United States, Illinois ... 展开 >> Rush University Medical Center Recruiting Chicago, Illinois, United States, 60612 Contact: Judy Phillips    312-942-0050    Judy_Phillips@rush.edu    United States, Kansas University of Kansas Clinical Research Center Recruiting Fairway, Kansas, United States, 66205 Contact: KUMC Recruitment Division    913-588-0555    KUAMP@kumc.edu    United States, Massachusetts Massachusetts General Hospital Recruiting Boston, Massachusetts, United States, 02114 Contact: Alison J McManus, DNP    617-643-4848    ajmcmanus@mgh.harvard.edu    Contact: John Ernandez    617-643-4047    jernandez@partners.org    United States, New Jersey Rowan University Not yet recruiting Stratford, New Jersey, United States, 08084 Contact: Lauren Fedor    856-566-6003    fedor@rowan.edu    United States, New York Mount Sinai Alzheimer's Disease Research Center Not yet recruiting New York, New York, United States, 10029 Contact: Caroline Meuser    212-659-8885    caroline.meuser@mssm.edu    Columbia University Recruiting New York, New York, United States, 10032 Contact: Ruth Tejeda    212-305-7661    rbt41@cumc.columbia.edu    United States, Pennsylvania Penn Memory Center Recruiting Philadelphia, Pennsylvania, United States, 19104 Contact: Laura Schankel    215-349-8727    laura.schankel@pennmedicine.upenn.edu 收起 <<

Tauroursodeoxycholate sodium 参考文献

[1]Alpini G, Kanno N, et al. Tauroursodeoxycholate inhibits human cholangiocarcinoma growth via Ca2+-, PKC-, and MAPK-dependent pathways. Am J Physiol Gastrointest Liver Physiol. 2004 Jun;286(6):G973-82.

[2]Milkiewicz P, Roma MG, et al. Effect of tauroursodeoxycholate and S-adenosyl-L-methionine on 17beta-estradiol glucuronide-induced cholestasis. J Hepatol. 2001 Feb;34(2):184-91.

[3]Paluschinski M, Castoldi M, Schöler D, Bardeck N, Oenarto J, Görg B, Häussinger D. Tauroursodeoxycholate protects from glycochenodeoxycholate-induced gene expression changes in perfused rat liver. Biol Chem. 2019 Nov 26;400(12):1551-1565

[4]Yang Y, He J, Suo Y, Zheng Z, Wang J, Lv L, Huo C, Wang Z, Li J, Sun W, Zhang Y. Tauroursodeoxycholate improves 2,4,6-trinitrobenzenesulfonic acid-induced experimental acute ulcerative colitis in mice. Int Immunopharmacol. 2016 Jul;36:271-276

[5]Ishizaki K, Kinbara S, Hirabayashi N, Uchiyama K, Maeda M. Effect of sodium tauroursodeoxycholate on phalloidin-induced cholestasis in rats. Eur J Pharmacol. 2001 Jun 1;421(1):55-60

Tauroursodeoxycholate sodium 实验方案

计算器
存储液制备 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.91mL

0.38mL

0.19mL

9.57mL

1.91mL

0.96mL

19.13mL

3.83mL

1.91mL

Tauroursodeoxycholate sodium 技术信息

CAS号35807-85-3
分子式C26H45NNaO6S
分子量 522.693
别名 牛磺熊脱氧胆酸钠 ;Tauroursodeoxycholic acid sodium;UR 906 sodium;Ursodeoxycholyltaurine sodium;TUDC;Sodium Tauroursodeoxycholate;TUDCA sodium
运输蓝冰
存储条件

液体 -20°C:3-6个月-80°C:12个月

粉末 Inert atmosphere,Store in freezer, under -20°C
溶解度

DMSO: 105 mg/mL(200.88 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

H2O: 100 mg/mL(191.32 mM)，配合低频超声助溶
动物实验配方

PO 0.5% CMC-Na 35 mg/mL clear

Tags: Tauroursodeoxycholate sodium | Tauroursodeoxycholic acid sodium;UR 906 sodium;Ursodeoxycholyltaurine sodium;TUDC;Sodium Tauroursodeoxycholate;TUDCA sodium | 牛磺熊脱氧胆酸钠 | ERK | AmBeed-信号通路专用抑制剂 | Tauroursodeoxycholate sodium 纯度/质量文件 | Tauroursodeoxycholate sodium 亚型比较 | Tauroursodeoxycholate sodium 生物活性 | Tauroursodeoxycholate sodium 临床数据 | Tauroursodeoxycholate sodium 参考文献 | Tauroursodeoxycholate sodium 实验方案 | Tauroursodeoxycholate sodium 技术信息

Ambeed 相关网站 Ambeed.cn Ambeed.com
Ambeed
关于我们
联系我们
资讯中心
网站地图
产品手册
  • 批次文件查询
    • 客户支持
    技术支持
    专业术语
    缩略词释义
    质量手册
    产品咨询
    计算器
    活动政策
    订购方法
    积分商城
    活动声明
    联系我们
    400-920-2911 sales@ambeed.cn tech@ambeed.cn
    Ambeed 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质用途提供服务。

    尊敬的 Ambeed 客户您好，
    请您选择所在区域，我们将转接对应客服为您服务！

    热门区域

    A

    B

    C

    F

    G

    H

    J

    L

    N

    Q

    S

    T

    X

    Y

    Z

    热 A B C F G H J L N Q S T X Y Z